PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Methylnaltrexone bromide - Constipation
PAD Profile : Methylnaltrexone bromide - Constipation Important
Brand Names Include :
Relistor
Important Information :
For opioid-induced constipation in terminally ill patients when response to other laxatives is inadequate
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Ispaghula husk
- Bisacodyl
- Glycerol
- Senna
- Lactulose
- Phosphates (Rectal)
- Co-danthrusate (Dantron/docusate sodium)
- Co-danthramer (Dantron/poloxamer 188)
- Sodium citrate (Rectal)
- Naldemedine
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
NICE TA277 Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced il
Committee Recommendations
Date
Committee Name
Narrative
26 October 2011
Not Set
Licensed for opioid induced constipation in terminally ill when response to other laxatives isinadequate. This injectable drug is considered as red on the traffic light system - please refer back to acute trust
Associated BNF Codes
01. Gastro-Intestinal System
01.06.06. Peripheral opioid-receptor antagonists